The C-TRACT trial, a phase III study, has shed light on the efficacy of endovascular therapy in treating post-thrombotic syndrome (PTS) and iliac-vein obstruction following deep vein thrombosis (DVT). The trial, conducted across 29 centers in the U.S., randomized 225 patients with moderate to severe PTS and confirmed iliac-vein obstruction to either the intervention group or the control group. The intervention group received iliac vein stent placement and enhanced antithrombotic therapy, while the control group received usual care, including compression stockings, anticoagulant therapy, and lifestyle guidance.
The results were compelling. Patients in the intervention group experienced a significant reduction in PTS severity, as measured by the Venous Clinical Severity Score tool, with a mean score of 8.1 compared to 10 points in the control group (P=0.001). This translates to a noticeable improvement in their quality of life, particularly in terms of venous disease-specific quality of life (P<0.001) and overall quality of life (P<0.001).
However, the trade-off for this improved outcome was an increased risk of bleeding. The intervention group had a higher incidence of overall bleeding (11% vs 3.6% in the control group, P=0.03), although major bleeding remained rare. This finding highlights the delicate balance between the benefits of endovascular therapy and the potential risks, particularly the increased risk of bleeding associated with enhanced antithrombotic therapy.
The study's authors, Suresh Vedantham, MD, and colleagues, emphasize the importance of iliac-vein outflow in DVT patients, aligning with the open-vein hypothesis. They suggest that eliminating chronic venous obstruction through stenting can significantly reduce the severity and symptoms of PTS. However, they also caution that the optimal antithrombotic regimen after stenting and the long-term durability of stents remain unanswered questions.
In an accompanying editorial, Ronald Luiz Gomes Flumignan, MD, PhD, and Luis Carlos Uta Nakano, MD, PhD, emphasize the need for further research. They argue that cost-effectiveness analyses and data beyond the initial 6 months are crucial before stenting can be incorporated into routine guidelines. The editorialists also stress the importance of shared decision-making, considering patient preferences, individual bleeding risk, access to experienced operators, and the realistic magnitude of expected benefits.
In conclusion, the C-TRACT trial provides valuable insights into the potential of endovascular therapy in managing PTS and iliac-vein obstruction. While it offers a promising approach to improving quality of life for carefully selected patients, the increased risk of bleeding and the need for further research should be carefully considered in clinical practice. As the medical community continues to explore these innovative treatments, it is essential to balance the potential benefits with the risks and uncertainties that remain.
